公开(公告)号：US20190161536A1

公开(公告)日：2019-05-30

申请号：US16197066

申请日：2018-11-20

Applicant: President and Fellows of Harvard College ,  UCB Biopharma SPRL

Inventor： Gökhan S. Hotamisligil ,  Mehmet F. Burak ,  Feyza Engin ,  Scott B. Widenmaier ,  Elisabeth Helen Roberts ,  Adrian Richard Moore ,  Carl Brendan Doyle ,  Ralph Adams ,  Karine Jeannine Madeleine Hervé ,  Shauna Mhairi Wales ,  Kerry Louise Tyson

IPC: C07K16/18 ,  A61K39/00

Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

公开(公告)号：US20190153028A1

公开(公告)日：2019-05-23

申请号：US16089443

申请日：2017-03-31

Applicant: UCB BIOPHARMA SPRL

Inventor： RICHARD JONES ,  JONATHAN SYMMONS ,  SASKIA HOCKING

IPC: C07K1/22 ,  C07K16/00 ,  B01J20/282 ,  C07K1/34 ,  C07K1/18 ,  B01D15/38 ,  B01D15/26 ,  B01D15/36 ,  B01D15/18

Abstract: The present invention provides a method for manufacturing antibodies or a fragment thereof with reduced levels of antibody reduction related impurities.

公开(公告)号：US20190144529A1

公开(公告)日：2019-05-16

申请号：US16098085

申请日：2017-04-28

Applicant: UCB BIOPHARMA SPRL

Inventor： Ralph ADAMS ,  Sam Philip HEYWOOD

IPC: C07K16/18 ,  C07K16/46

Abstract: The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.

公开(公告)号：US20190142759A1

公开(公告)日：2019-05-16

申请号：US16241184

申请日：2019-01-07

Applicant: UCB Biopharma SPRL

Inventor： Domenico Fanara ,  Frederic Eeckman ,  Monique Berwaer

IPC: A61K9/50 ,  A61K47/38 ,  A61K9/16 ,  C07D207/27 ,  A61K31/4015 ,  A61K47/32

Abstract: The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

公开(公告)号：US20190119302A1

公开(公告)日：2019-04-25

申请号：US16086418

申请日：2017-03-31

Applicant: UCB Biopharma SPRL ,  Sanofi

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer

IPC: C07D519/00 ,  C07D487/22

Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20190119206A1

公开(公告)日：2019-04-25

申请号：US15772607

申请日：2016-10-27

Applicant: UCB Biopharma SPRL

Inventor： Thierry DEFRANCE ,  Jean SEPTAVAUX ,  Didier NUEL

IPC: C07D207/27

CPC classification number: C07D207/27 ,  C07D207/26

Abstract: The present invention relates to a new process for preparing brivaracetam. (Ib)

公开(公告)号：US20190100525A1

公开(公告)日：2019-04-04

申请号：US16086408

申请日：2017-03-31

Applicant: UCB Biopharma SPRL ,  Sanofi

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Jean Keyaerts ,  Luce Elsa Lepissier ,  Martin Alexander Lowe

IPC: C07D487/18

Abstract: A series of substituted fused pentacyclic benzimidazole derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20190083617A1

公开(公告)日：2019-03-21

申请号：US16083321

申请日：2017-03-09

Applicant: UCB BIOPHARMA SPRL

Inventor： Andrew Jeffrey Yates ,  James Gregory Clipstone

IPC: A61K39/395 ,  C07K16/22 ,  A61K47/40 ,  A61K47/20

Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis. Furthermore, the invention relates to a method of reducing inflammation at injection site in a mammalian subject comprising administering a therapeutically effective amount of a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine.

公开(公告)号：US10202405B2

公开(公告)日：2019-02-12

申请号：US15513357

申请日：2015-10-02

Applicant: UCB Biopharma SPRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm Mac Coss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07F7/18 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D491/08 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D495/18 ,  C07D513/18

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.

公开(公告)号：US20180362532A1

公开(公告)日：2018-12-20

申请号：US16060486

申请日：2016-12-08

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven

Inventor： Helen Tracey Horsley ,  Richard John Mears ,  Judi Charlotte Neuss ,  James Thomas Reuberson

IPC: C07D487/04 ,  C07D519/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06 ,  A61P33/06 ,  A61P31/12

CPC classification number: C07D487/04 ,  A61K31/4985 ,  A61P29/00 ,  A61P31/12 ,  A61P33/06 ,  A61P35/00 ,  A61P37/06 ,  C07D519/00

Abstract: A series of 1,2,6,7,9,9a-hexahydropyrazino[1,2-d][1,2,4]triazin-4-one derivatives, substituted in the 8-position by an optionally substituted fused bicyclic heteroaromatic group, and in the 3-position by a range of functional groups, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.